Osiris Stock Soars (OSIR)

NEW YORK ( TheStreet) -- Shares of Osiris Therapeutics (Nasdaq: OSIR) have taken a tremendous swing upward. The stock is trading at $6.85 as of 1:10 p.m. ET, 23.4% above Friday's closing price of $5.55. Volume is at 525,865, six times the daily average of 87,500.

Osiris has a market cap of $172.8 million and is part of the health care sector and drugs industry. Shares are up 3.7% year to date as of the close of trading on Friday.

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Therapeutics and Biosurgery. The company has a P/E ratio of 18.1, below the average drugs industry P/E ratio of 18.8 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Osiris as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. You can view the full Osiris Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.
null

If you liked this article you might like

MiMedx Goes After Osiris With Lawsuit

MiMedx Goes After Osiris With Lawsuit

Buy These 5 Breakout Stocks Now for Big Gains

Buy These 5 Breakout Stocks Now for Big Gains

Osiris Therapeutics (OSIR) Weak On High Volume Today

Osiris Therapeutics (OSIR) Weak On High Volume Today

'Mad Money' Lightning Round: I'm Not Abandoning Rite Aid

'Mad Money' Lightning Round: I'm Not Abandoning Rite Aid

Jim Cramer's 'Mad Money' Recap: Be Patient, Then Start Buying

Jim Cramer's 'Mad Money' Recap: Be Patient, Then Start Buying